Daniela Bota

Dean and Professor at School of Medicine, University of California-Irvine0 Followers

Dedicated to advancing knowledge in the field of neurology, Daniela Bota serves as a Professor of Neurology at the UCI School of Medicine. With a strong commitment to clinical science, she also holds the position of Vice Dean for Clinical Science, where she plays a pivotal role in shaping the future of medical education and research at the university. Professor Bota's work is centered around enhancing patient care and fostering innovative research initiatives. Her leadership at the School of Medicine University of California-Irvine is marked by a focus on integrating clinical practice with academic excellence. She is accessible for professional inquiries at 200 S. Manchester Drive, Orange, CA 92868-3217, or via phone at 714-456-8000.

Research Interests

Neurology clinical science patient care medical education innovative research initiatives

Publications

1 - Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain,Cancer Research

Daniela A. Bota , Kaijun Di , David B. Keator , Robert G. Bota , Matthew Hoffmann , C. Dan Dumitru , Nancy Levin ,

, 4733-4733, 2019-07-01

2 - Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma,Cancer Research

Kaijun Di , Xing Gong , Dana M. Curticiu , Michael A. Palladino , Daniela A. Bota ,

, 1809-1809, 2014-10-01

3 - Abstract 5959: Targeting TRIM11 is a potential therapeutic strategy for malignant gliomas,Cancer Research

Kaijun Di , Bhaskar C. Das , Daniela Alexandru Abrams , Daniela A. Bota ,

, 5959-5959, 2024-03-22

4 - Abstract 4782: Cisplatin induces mitochondrial damage and hippocampal neurotoxicity: a potential mechanism for chemotherapy-related cognitive impairment,Cancer Research

Naomi Lomeli , Jennifer Czerniawski , Kaijun Di , John Guzowski , Daniela Bota ,

, 4782-4782, 2016-07-15

5 - Abstract 3757: The development of MAGMAS as a potential therapeutic target in temozolomide-resistant glioma,Cancer Research

Jennifer D. Tran , Javier J. Lepe , Maria C. Kenney , Bhaskar C. Das , Daniela A. Bota ,

, 3757-3757, 2024-03-22

6 - Abstract 3069: Investigation of pharmacodynamic and predictive biomarkers to define response to proteasome inhibitor marizomib in glioma,Cancer Research

Daniela Bota , Annick Desjardins , Warren Mason , Kaijun Di , Ann P. MacLaren , Nancy Levin , Mohit Trikha ,

, 3069-3069, 2016-07-15

7 - Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis,Journal of Neurosurgery

Daniela A. Bota , Daniela Alexandru , Stephen T. Keir , Darell Bigner , James Vredenburgh , Henry S. Friedman ,

, 1415-1423, 2013-12-01

8 - Abstract 3180: Suppression of the CPEB3 ribozyme modulates the progression of glioblastoma,Cancer Research

Claire Chen , Eric Wang , Lily Tong , Mehran Nikan , Daniela A. Bota , Claudia Benavente , Andrej Luptak ,

, 3180-3180, 2024-03-22

9 - Abstract 331: Characterization of neoepitope (neoE)-specific T cells from peripheral blood for adoptive neoTCR-T cell therapy for patients with breast cancer (bc) or ovarian cancer (oc),Cancer Research

Mihaela Cristea , Bartosz Chmielowski , David Y. Oh , Roel P. Funke , Daniela A. Bota , Mehrdad Abedi ,

, 331-331, 2021-07-01

10 - Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy,American Journal of Therapeutics

Alina Bisoc , Daniel Ciurescu , Mariana Rădoi , Monica M. Tântu , Liliana Rogozea , Alexander J. Sweidan , Daniela A. Bota ,

, e142-e150, 2020-03-01

11 - Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy.,Journal of Clinical Oncology

Andres Felipe Guerrero Ramirez , Cynthia Crystal Tang , Xiao-Tang Kong , Daniela Annenelie Bota , Peter D. Chang ,

, e14032-e14032, 2024-06-01

12 - NCMP-18. NEUROLOGICAL SEQUELAE IN THE ID8 OVARIAN CANCER MOUSE MODEL: P38/JNK MAPK INHIBITION AS A POTENTIAL THERAPEUTIC FOR CANCER-RELATED COGNITIVE IMPAIRMENTS AND CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY,Neuro-Oncology

Naomi Lomeli , Martha Garcia , Donovan Argueta , Kalpna Gupta , Daniela Bota ,

, vii194-vii195, 2022-11-01

13 - NCMP-16. THE ROLE OF p38 AND JNK MAPK PATHWAYS IN CISPLATIN CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENT,Neuro-Oncology

Naomi Lomeli , Kaijun Di , Daniela Bota ,

, ii126-ii126, 2020-11-01

14 - EXTH-19. EVALUATING THE ANTI-TUMOR EFFECT OF A NOVEL THERAPEUTIC AGENT, MAGMAS INHIBITOR, IN MALIGNANT GLIOMA,Neuro-Oncology

Kaijun Di , Senjie Du , Javier Lepe , Nitesh Nandwana , Bhaskar Das , Daniela Bota ,

, ii90-ii91, 2020-11-01

15 - NCMP-13. ID8 OVARIAN CANCER MOUSE MODEL MIMICS NEUROLOGICAL SEQUELAE OF OVARIAN CANCER IN WOMEN,Neuro-Oncology

Naomi Lomeli , Daniela Bota , Donovan Argueta , Kalpna Gupta ,

, vi149-vi149, 2021-11-02

16 - CTNI-83. PROPOSAL FOR A PILOT PHASE 1B CLINICAL TRIAL WITH ADDITION OF NATURAL MARINE PRODUCT FUCOIDAN TO ANTI-NEOPLASTIC THERAPY FOR PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM) TO IMPROVE FATIGUE AND OTHER HEALTH-RELATED QUALITY OF LIFE (HRQOL) SYMPTOMS,Neuro-Oncology

Xiao-Tang Kong , Carlen A Yuen , Yoon Jae Choi , Yoshiyuki Miyazaki , Daniela A Bota , Geoffrey Winston Abbott ,

, viii116-viii117, 2024-11-01

Share Daniela's Profile